FDA expands indication for Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) HPV vaccine- Merck

The FDA has approved an expanded age indication for Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant), to now include use in males 16–26 years of age, for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11.

Gardasil 9 is already approved for use in boys 9–15 years of age for the prevention of these diseases. Gardasil 9 is also approved for use in girls and young women 9–26 years of age for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58, and genital warts caused by HPV types 6 and 11.